Investigation of tyrosine kinase gene mutation using real-time PCR assay

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592097
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Thoracic surgery
• Research Institution: Nagoya City University
• Principal Investigator: SASAKI Hidefumi 名古屋市立大学, 医学(系)研究科(研究院), 研究員 (00336695)
• Co-Investigator(Kenkyū-buntansha): YANO Motoki 名古屋市立大学, 大学院医学研究科, 准教授 (40315833) ; OKUDA Katsuhiro 名古屋市立大学, 大学院医学研究科, 助教 (50529170)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: BRAF / EGFR / RET / FGFR3 / CAST-PCR / 肺癌

Outline of Final Research Achievements

Molecular targeted therapies such as erlotinib or gefitinib that target EGFR mutations and crizotinib that target ALK fusion have demonstrated superior single agent activity in selected patients as compared to standard chemotherapy regimes in lung cancer treatment. Recently, a series of new gene fusions have been described in patients with lung cancer using next generation sequencing. In 2012, we have discovered RET translocation in lung adenocarcinomas. In our cohort, three RET fusion mutants were found. We have developed FISH probes to detect RET translocations. in 2013, we have discovered NTRK1 translocation in lung adenocarcinomas. in 2014, we have discovered FGFR3 translocations in lung adenocarcinomas. In addition, BRAF V600E is a driver mutation that can be effectively targeted with selective BRAF inhibitors. To determine the BRAF mutation status in Japanese lung carcinoma, we investigated BRAF V600E mutations by real time-PCR (CAST-PCR) and immunohistochemical methods.

Free Research Field

呼吸器外科学